Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Rituximab is a standard treatment for non-Hodgkin lymphoma. The SABRINA trial (NCT01200758) showed that a subcutaneous (SC) rituximab formulation did not compromise efficacy or safety compared with intravenous (IV) infusion. We aimed to quantify active healthcare professional (HCP) time and patient chair time for rituximab SC and IV, including potential time savings. METHODS: This non-interventional time and motion study was run in eight countries and 30 day oncology units. Rituximab SC data were collected alongside the MabCute trial (NCT01461928); IV data were collected per routine real-world practice. Trained observers recorded active HCP time for pre-specified tasks (stopwatch) and chair time (time of day). A random intercept model was used to analyze active HCP time (by task and for all tasks combined) in the treatment room and drug preparation area, drug administration duration, chair time and patient treatment room time by country and/or across countries. Active HCP and chair time were extrapolated to a patient's first year of treatment (11 rituximab sessions). RESULTS: Mean active HCP time was 35.0 and 23.7 minutes for IV and SC process, respectively (-32%, p <0.0001). By country, relative reduction in time was 27-58%. Absolute reduction in extrapolated active HCP time (first year of treatment) was 1.1-5.2 hours. Mean chair time was 262.1 minutes for IV, including 180.9 minutes infusion duration, vs. 67.3 minutes for SC, including 8.3 minutes SC injection administration (-74%, p <0.0001). By country, relative reduction was 53-91%. Absolute reduction in extrapolated chair time for the first year of treatment was 3.1-5.5 eight-hour days. CONCLUSIONS: Compared with rituximab IV, rituximab SC was associated with reduced chair time and active HCP time. The latter could be invested in other activities, whereas the former may lead to more available appointments, reducing waiting lists and increasing the efficiency of day oncology units. TRIAL REGISTRATION: ClinicalTrials.gov NCT01200758.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Significant cost savings were also seen in various other countries [7, 8, 44–47].”
From Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities (2018) · cites this paper as [8]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Preparation time or pharmacist time per infusion of rituximab was reported in five publications and ranged from 4–40 min (IV) to 2–20 min (SC) [66, 88, 90, 91, 104].”
From A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting (2023) · cites this paper as [88]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Nineteen publications (seven full publications [52, 66, 88–92] and 12 abstracts [93–104]) reported data on time required, or differences in time required, for IV versus SC rituximab for the treatment of lymphoma (NHL/FL or DLBCL in most publications) (Fig. 2).”
From A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting (2023) · cites this paper as [88]
The cited source says what the claim attributes to it.
In the citing paper
“Time savings with SC administration were ~200 min [66, 88, 92, 97].”
From A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting (2023) · cites this paper as [88]
In the citing paper
“Similar variations were also seen with studies of rituximab [88]; however, a consistent trend in favor of SC administration was observed across all publications.”
From A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting (2023) · cites this paper as [88]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., Rosso, S., Coebergh, J. W. W., Comber, H., Forman, D., & Bray, F. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.027 · Cited by 5,263
McCambridge, J., Witton, J., & Elbourne, D. R. (2014) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.08.015 · Cited by 2,748 · cited 1×
“, potential change in HCP behavior because of being directly observed) [20].”
BackgroundPivot, X., Gligorov, J., Müller, V., Barrett-Lee, P., Verma, S., Knoop, A., Curigliano, G., Semiglazov, V., López-Vivanco, G., Jenkins, V., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70383-8 · Cited by 230
Davies, A., Merli, F., Mihaljevic, B., Siritanaratkul, N., Solal-Céligny, P., Barrett, M., Berge, C., Bittner, B., Boehnke, A., McIntyre, C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70005-1 · Cited by 114 · cited 2×
“Similarly, the SABRINA study showed that rituximab SC shortened administration time to approximately five to seven minutes [11].”
BackgroundMethodDe Cock, E., Pivot, X., Hauser, N., Verma, S., Kritikou, P., Millar, D., & Knoop, A. (2016) · Cancer Medicine · doi:10.1002/cam4.573 · Cited by 112
Self-citationMonoclonal Antibodies in the Treatment of Non-Hodgkin???s Lymphoma
Fanale, M. A., & Younes, A. (2007) · Drugs · doi:10.2165/00003495-200767030-00002 · Cited by 111
Rituximab: A New Therapeutic Monoclonal Antibody for Non‐Hodgkin's Lymphoma
Scott, S. D. (1998) · Cancer Practice · doi:10.1046/j.1523-5394.1998.006003195.x · Cited by 105
Salar, A., Avivi, I., Bittner, B., Bouabdallah, R., Brewster, M., Catalani, O., Follows, G., Haynes, A., Hourcade-Potelleret, F., Janikova, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.2631 · Cited by 98
(2006) · European Journal of Haematology · doi:10.1111/j.1600-0609.2006.00789.x · Cited by 89
Rule, S., Collins, G. P., & Samanta, K. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2014.914033 · Cited by 66 · cited 3×
“This was observed in the UK, where mean pharmacy technician time for rituximab IV was shifted to pharmacist time for rituximab SC, resulting in somewhat higher drug preparation costs for rituximab SC, as a result of higher pharmacist salary [14].”
Background
Research works printed but not linked: 1
- Rummel M, Kim TM, Plenteda C, Capochiani E, Mendoza M, Smith R, et al Patient preference for subcutaneous or intravenous administration of rituximab in previously untreated CD20+ non-Hodgkin lymphoma: interim data from the PrefMab study. Haematologica (EHA annual congress abstracts). 2014; 99:Poster 467.
Cited by
Items 101–117 of 117
USE OF MONOCLONAL ANTIBODIES TO HUMAN CYTOKINES IN DIAGNOSTIC AND ANALYTICAL STUDIES
Akhmedova, V. A. (2024) · Biotechnologia Acta · doi:10.15407/biotech17.04.024
Montalbán, X., Rodríguez‐Acevedo, B., Nos, C., Resina, M., Forner, M., Wu, Y., & Chirieac, M. (2024) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864241291655
Duran, M., & Beğendi, N. K. (2025) · Medical Records · doi:10.37990/medr.1658891
Frank, S. (2024) · heiDOK (Heidelberg University) · doi:10.11588/heidok.00029166
Abad-Sazatornil, M. R., Arenaza, A., Bayo, J. L., Mata, J. G., Guinea De Castro, J. M., León, J., Letellez, J., Reguero, V., Martínez Chamorro, C., & Salar, A. (2021) · Figshare · doi:10.6084/m9.figshare.14391300
Deep Eutectic-Mediated Parenteral Drug Delivery Systems for Therapeutic Macromolecules
Curreri, A. M. (2023) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Cock, E. D., Jomaa, K., Menon, J., Acosta, C., Esquejo-Leon, R. L., & Oliver-Smith, P. (2026) · Neurology and Therapy · doi:10.1007/s40120-026-00888-1
Graff, T., Chawla, S. B., Jun, M. P., Heaps, N., Alshreef, A., Tybor, D. J., Moore, D. C., Zawadzki, N. K., Spurrier, K., & Shafrin, J. T. (2026) · Future Oncology · doi:10.1080/14796694.2026.2636559
Guinan, K., Pelletier, M., Ham, M., Tankala, D., Roc, N. P., Klil-Drori, A. J., Wang, A., Fleury, I., Macdonald, D. A., Lachaîne, J., et al. (2026) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2025-0187
Fiordelisio, T., Valdés-Souto, F., Del-Rio, D., Zamarrón-Hernández, D., Pulido, K. R., Soto, C. A. E., Trejo, Y. U. C., Sánchez, C. I. G., Gutiérrez, I. E., & Salinas, C. H. A. (2026) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2025-0199
Filippi, M., Grimaldi, L. M. E., Morra, V. B., Conte, A., Cordioli, C., Totaro, R., Lus, G., Rini, A., Marinelli, F., Valentino, P., et al. (2026) · Journal of Neurology · doi:10.1007/s00415-026-13977-w
Zorzetto, G., Russi, A., Giuriola, A., Blasio, G. D., Lonardi, S., Guarneri, V., Maruzzo, M., Dieci, M. V., Pasello, G., Gottardi, M., et al. (2026) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462326104000
Avellá, M. L., Carmo, M., Duran, N., & Parcerisa, P. B. (2026) · PLoS ONE · doi:10.1371/journal.pone.0358426
Toward industrial microalgae-based monoclonal antibody production
Garwood, M. M., Ross, I. L., & Hankamer, B. D. (2026) · Trends in biotechnology · doi:10.1016/j.tibtech.2026.10.003
Delmas, A., Batchelder, L., Arora, I., Bayet, S., Bruhn, D., Eberhardt, A., Philpott, S., & Rodriguez-Leboeuf, A. M. (2023) · doi:10.3389/fonc.2023.1160966.s001
Metadata
- Authors
- De Cock, E., Kritikou, P., Sandoval, M., Tao, S., Wiesner, C., Carella, A. M., Ngoh, C., & Waterboer, T.
- Affiliations
- United BioSource Corporation (United Kingdom) (GB)
- Concordia University (CA)
- Genentech (US)
- Ospedale Policlinico San Martino (IT)
- F. Hoffmann-La Roche AG (CH)
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-06-30
- Volume
- 11
- Issue
- 6
- Pages
- e0157957
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4928781
- OpenAlex
- W2472310215
- Cited by
- 108
- References
- 16
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 15 · 2023: 11 · 2022: 6 · 2021: 13 · 2020: 8 · 2019: 11 · 2018: 10 · 2017: 10 · 2016: 1
- FWCI
- 9.68
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- F. Hoffman-La Roche
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Social Sciences › Decision Sciences › Management Science and Operations Research › Healthcare Operations and Scheduling Optimization
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- rituximab, subcutaneous administration, intravenous infusion, non-Hodgkin lymphoma, treatment efficiency
- MeSH terms
- Rituximab, Antineoplastic Agents, Humans, Infusions, Intravenous, Injections, Subcutaneous, Lymphoma, Non-Hodgkin, Time and Motion Studies, Time Factors, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.